Dr. Yie-Hwa Chang founded the Company in August 2001 as a Missouri Limited Liability Corporation (LLC). The Company currently holds four core proprietary technologies:

1. a DNA-binding protein-based bioassay/biosensor/biochip platform;
2. the PINCER™-based homogeneous biosensor, bioassay and biochip platform
3. innovative, proprietary methods to screen and develop new high-affinity capture reagents for research, diagnostic and therapeutic use and anti-angiogenesis related therapies.

   Mediomics is currently focusing on developing a sustainable, profitable biotechnology business that provides innovative assay kits, biosensors and microarrays needed by academic research laboratories, point of care testing, pharmaceutical companies, as well as medical and environmental research markets. These quick and simple assay kits will be used to quantify many of the most biologically and therapeutically important macromolecules, including ligands, proteins, protein complexes, bacteria, fungi and viruses.

   In addition, Mediomics’ platform technologies will be able to generate entirely new biomaterials, which can be used for assay development as well as for the development of therapeutic products. Mediomics has successfully competed for a number of highly selective state and federal grants and subcontracts (~ 3 million in total), with awards to date including SBIR Phase I and II grants from the National Science Foundation, STTR Phase I and II grants from the National Institutes of Health, subcontracts from the Department of Homeland Security, and a subcontract from the Leonard Wood Institute.